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Abstract
Anxiolytic and anxiogenic-like behavioral outcomes have been reported for methylenedioxymethamphetamine (MDMA or 
ecstasy) in rodents. In the present experiment, we attempted to identify behavioral, hormonal and neurochemical outcomes of 
MDMA treatment to clarify its effects on anxiety-related responses in 2-month-old BALB/c male mice (25-35 g; N = 7-10 mice/
group). The behavioral tests used were open field, elevated plus maze, hole board, and defensive behavior against predator 
odor. Moreover, we also determined striatal dopamine and dopamine turnover, and serum corticosterone levels. MDMA was 
injected ip at 0.2, 1.0, 5.0, 8.0, 10, or 20 mg/kg. MDMA at 10 mg/kg induced the following significant (P < 0.05) effects: a) a 
dose-dependent increase in the distance traveled and in the time spent moving in the open field; b) decreased exploratory 
activity in the hole board as measured by number of head dips and time spent in head dipping; c) increased number of open- 
arm entries and increased time spent in open-arm exploration in the elevated plus maze; d) increased time spent away from an 
aversive stimulus and decreased number of risk assessments in an aversive odor chamber; e) increased serum corticosterone 
levels, and f) increased striatal dopamine level and turnover. Taken together, these data suggest an anxiogenic-like effect of 
acute MDMA treatment, despite the fact that behavioral anxiety expression was impaired in some of the behavioral tests used 
as a consequence of the motor stimulating effects of MDMA.
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3-4,Methylenedioxymethamphetamine (MDMA or ec-
stasy) is a synthetic drug used for recreational purposes, 
mainly by young people. MDMA is as potent neurotrans-
mitter releaser in the central nervous system (CNS) with 
psychostimulant properties in animals and humans (1,2). 
In addition, MDMA induces hyperthermia, increases heart 
rate, activates the hypothalamo-pituitary-adrenal (HPA) axis, 
and also induces immunological alterations (3-6). 
Anxiolytic and anxiogenic-like behavioral outcomes have 
been extensively studied in MDMA-treated animals using 
a variety of anxiety models (7,8). However, a noteworthy 
feature is that contradictory results have been shown 
depending on the test, dose, gender, and latency after the 
drug treatment (7,9). Navarro and Maldonado (10) showed 
in a model of social interaction that the treatment with 5 or 
20 mg/kg MDMA produced an anxiogenic-like response. 
Maldonado and Navarro (11) also observed contradictory 
effects of MDMA treatment. In the light-dark box test, they 
showed an increased latency to move from the lit to the 
dark compartment, which is consistent with an anxiolytic-
like activity of MDMA (11). However, they stated that a 
social interaction test would be more sensitive to detect an 
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anxiogenic-like response induced by MDMA.
These contradictory results have led some investigators 
to suggest that high doses of MDMA could be anxiolytic 
and low doses could be anxiogenic (12) in the elevated 
plus maze. However, in a more detailed study, Morley and 
McGregor (8), using cat odor and shock-induced ultrasonic 
vocalization tests in the elevated plus maze, showed that 
MDMA administration induced an anxiogenic-like effect, 
while in the social interaction test MDMA induced an anx-
iolytic-like effect (8), a test that had already been reported 
to be anxiogenic in animals treated with the drug (10,11). 
Therefore, the investigators suggested that MDMA has both 
anxiogenic- and anxiolytic-like effects depending upon the 
test and the situation employed (7-9).
Hence, based on these contradictory results found in 
the literature, our goal was to search for behavioral and 
neurochemical outcomes of MDMA treatment in mice in 
an attempt to clarify its effects on anxiety-like responses. 
Thus, mice were treated with MDMA and first analyzed in 
the open field and later in the elevated plus maze. Previous 
results from our group and others have shown that testing 
animals in an open field or in a hole board immediately 
before the elevated plus-maze test significantly elevates 
animal activity within this apparatus, i.e., the total number 
of open- and closed-arm entries (13,14), with a consequent 
simplification of analysis of the elevated plus-maze data. 
We also tested MDMA-treated mice in the hole-board test, 
since it has been indicated that head-dipping behavior is 
sensitive to changes in the emotional state of the animal, 
and the expression of an anxiolytic-like state in animals 
might be reflected by an increase in frequency and time of 
head-dipping (15). Predator odor test was also used here 
to address this issue since fear of a potential predator is 
known to trigger emotional states such as anxiety. Ad-
ditionally, hormonal (corticosterone) and neurochemical 
(dopaminergic activity in the striatum) analyses were also 
performed in MDMA-treated mice in order to better char-
acterize the behavioral phenomena observed.
Material and Methods
Animals
Male BALB/c mice from our own colony, weighing 25-35 
g and about 60 days of age, were used. The animals were 
housed in controlled-temperature (22-26°C) and artificially 
lighted rooms on a 12-h light/12-h dark cycle (lights on at 
7:00 am) with free access to rodent chow and water. The 
experiments were performed in a different room with the 
same temperature as the animal colony to which the animals 
were transferred and maintained in their home cages 7 days 
before the beginning of the experiments. Animals were 
housed and used in accordance with the guidelines of the 
Committee on Care and Use of Laboratory Animal Resources 
of the Faculdade de Medicina Veterinária e Zootecnia, 
Universidade de São Paulo (Protocol #1224/2007). 
Drugs
MDMA was extracted from tablets kindly provided by 
the Brazilian Federal Police Department (Brazil). Upon 
arrival at the laboratory, the drug was extracted and puri-
fied by employing liquid-liquid extraction for the isolation 
of 3,4-methylenedioxymethamphetamine (MDMA) from 
ecstasy tablets and afterwards MDMA was crystallized to 
MDMA hydrochloride (MDMA.HCl) as suggested by Lacava 
et al. (16). The obtained MDMA (99% homogeneity) was 
dissolved in 0.9% NaCl to concentrations ranging from 0.2 to 
20.0 mg/kg. Vehicle (0.9% NaCl) was administered  alone to 
the mice of the control group. Solutions were administered 
intraperitoneally (ip) in a volume of 0.1 mL/10 g.
Behavioral studies
To minimize the influence of possible circadian changes 
on the analyzed behaviors, control and experimental animals 
were alternated for observation, being always analyzed 
at the same time of day (between 8:00 and 12:00). The 
experimental devices used were cleaned with 5% ethanol 
in water and dried before exchanging each animal in order 
to obviate possible biasing effects due to odor clues left by 
previous mice.
Open field
Briefly, the open-field apparatus consists of a round 
wooden arena (40 cm in diameter, 20-cm high walls) 
painted black and virtually divided by software (EthoVision 
System®, version 1.9; Noldus Information Technology, 
USA) into two zones: central (center + median) and periph-
eral (external + thigmotaxis). The apparatus was elevated 
55 cm above the floor. For the observations, each mouse 
was individually placed in the center of the apparatus. 
Parameters measured included distance traveled (cm), 
time traveling (s), mean velocity (cm/s), rearing (N), and 
grooming (N) in each zone. A video camera mounted 100 
cm above the arena was used to collect the data that were 
analyzed with the EthoVision System® software installed 
on a compatible computer placed in an adjacent room.
Elevated plus maze
The elevated plus maze was made of wood, painted 
black, and had two open arms (25 x 5 cm) and two en-
closed arms of the same size with 15-cm high walls. The 
apparatus was elevated 55 cm above the ground. Each 
mouse was placed individually in the central square of the 
elevated plus-maze apparatus and allowed 5 min of free 
exploration. Each mouse was observed using the same 
system as described above for the open field (EthoVision 
System® software). The parameters recorded were: a) 
number of entries into the open and closed arms, b) time 
spent exploring the open and closed arms, c) distance 
traveled, d) time spent moving in the arena, e) rearing 
(N), f) risk assessment (N), and g) total arm entries. The 
measures that reflect anxiety-like levels in this test are 
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the percentage of entries into open arms versus closed 
arms and the percentage of time spent in the open arms 
versus closed arms.
Hole board
The hole-board apparatus was painted black and is 
similar to that validated for mice by File and Wardill (17). 
Briefly, it consists of a circular wooden arena (40 cm in 
diameter with 20-cm high walls), with four equally spaced 
holes (3 cm in diameter) on the floor. Two pellets of food 
(holes 1 and 3) and two plastic toys (holes 2 and 4) were 
placed underneath the holes. The areas around the holes 
were virtually marked using the EthoVision System®  soft-
ware and called “exploration zone”. The holes are placed 
in an intermediary zone and are equidistant from each 
other. The apparatus was elevated 60 cm from the ground. 
For the observations, each mouse was individually placed 
in the center of the apparatus and observed for 5 min 
using the system described above (Ethovision System® 
software). The following parameters were measured and 
analyzed: distance traveled (cm), mean velocity (cm/s), 
number (N), and time (s) of head dippings. 
Defensive behavior in response to predator odor
The apparatus used was constructed as described by 
Yang et al. (18). Briefly, it consists of a chamber divided 
into three compartments: a) home chamber, b) tunnel, and 
c) exposure cage. The home chamber was a 7 x 7 x 12 
cm box made of three black sides and one clear side to 
facilitate videotaping. The home chamber was connected 
to the exposure cage by a clear tube tunnel (4.4 cm in 
diameter, 13 cm in length, and elevated 1.5 cm from the 
floor of the two chambers). The exposure cage was a 46 
x 24 x 21 cm clear polycarbonate cage covered with a 
metal lid and divided into two equal-sized compartments 
by a wire mesh screen. In our protocol, a piece of fabric 
on which a cat had slept for 30 days was placed inside the 
right side compartment of the exposure cage to act as a 
predator stimulus of cat odor. Entries in the contact zone 
were considered when mice stood near the wire mesh 
screen. The animals were recorded using a horizontally 
mounted video camera. Prior to the beginning of each trial, 
the home cage bedding of each subject was placed on the 
floor of the apparatus. The testing procedure consisted of 
two phases: a) Habituation: each animal was placed on 
the left side of the exposure cage in the absence of cat 
odor. Each animal was allowed to explore for 10 min for 
3 consecutive days; b) test: each animal was placed on 
the left side of the exposure cage in the presence of cat 
odor, which was placed in the right side compartment, 
and animals were recorded for 10 min. The following pa-
rameters were analyzed: time in home chamber (s), time 
in tunnel (s), entries into the exposure cage (N), entries 
into the contact zone (near the wire mesh screen; N), risk 
assessment (N), and grooming (N).
Neurochemical measurements
Animals were euthanized by decapitation and the 
brains were immediately removed and dissected, with 
the striatum being excised as quickly as possible (over a 
period of no more than 3 min), then weighed and frozen on 
dry ice. Samples were homogenized by sonication in 0.1 
M perchloric acid containing 1.1 mM sodium metabisulfite 
and 0.54 mM disodium EDTA, and centrifuged for 30 min at 
11,200 g. The supernatants were stored frozen at -80°C until 
analysis. Dopamine (DA) and its metabolites homovanillic 
acid (HVA) and dihydroxyphenylacetic acid (DOPAC) were 
measured using a high performance liquid chromatography 
system (model 6A, Shimadzu, Japan) with an electrochemi-
cal detector (model 6A, Shimadzu) as described in detail 
elsewhere (19). Briefly, samples (20 µL) were loaded into 
a sample injector and the mobile phase was delivered at 
a constant rate of 0.5 mL/min through a C18 analytical 
column (Shimpak, ODS, Japan) placed inside a column 
heater (35°C). The mobile phase, pH 2.9, consisted of 0.02 
M disodium phosphate, 0.02 M citrate, 0.11 mM disodium 
EDTA, 2.75 mM heptanesulfonic acid, and 10% methanol. 
The signal from the detector was recorded with an integrator 
(Chromatopac, Shimadzu) and the run time for each sample 
was 25 min. Inter- and intra-assay coefficients of variation 
were smaller than 15% and the recovery rates higher than 
80% for both substances. The concentrations of DA, HVA 
and DOPAC are reported as ng/g tissue.
Serum corticosterone determination
Corticosterone was determined in serum using com-
mercially available kits (Coat-a-Count, DPC, USA). This 
procedure is based on a solid-phase radioimmunoassay 
in which 125I-labeled corticosterone competes for antibody 
sites for a fixed time with the corticosterone present in the 
murine sample. Serum samples were assayed directly 
without extraction or purification. To decrease the variability 
of serum corticosterone levels, the mice were handled daily 
for a period of 7 days for habituation to the experimental 
conditions to be used later for euthanasia and blood col-
lection. Animals were euthanized by decapitation and in 
order to minimize the reported circadian variations of serum 
glucocorticoid levels, control and experimental animals 
were intermixed for euthanasia and the blood was taken 
at the same time of day, i.e., between 8.00 and 9.00 am, 
30, 60, and 120 min after the administration of MDMA or 
0.9% NaCl.
Experimental design
Six experiments were performed in accordance with 
Good Laboratory Practices (GLP) standards and quality 
assurance methods: a) mice were randomly treated with 
MDMA (0.2, 1.0, 5.0, 8.0, 10, or 20 mg/kg) or 0.9% NaCl. 
After 60 min, each mouse was placed in the center of the 
open field and allowed to explore it for 5 min; b) mice were 
randomly treated with MDMA (5.0 or 10 mg/kg) or 0.9% 
Figure 1. Behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) 
on BALB/c male mice in the open-field test. A, Distance traveled and B, time 
spent in movement during the 5 min of the test (total arena, peripheral and cen-
tral zones). Data are reported as means ± SEM for 7-8 animals/group. *P < 0.05 
compared to control (one-way ANOVA followed by Dunnett’s multiple compari-
son test or Kruskal-Wallis test followed by Dunn’s multiple comparison test).
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NaCl. After 60 min, each mouse was placed in the center of 
the hole board and allowed to explore it for 5 min; c) mice 
received 10 mg/kg MDMA or 0.9% NaCl in a random order 
and after 60 min were placed in the center of the open field 
and allowed to explore it for 5 min. The animals previously 
observed in the open field were then immediately tested 
individually in the elevated plus maze for an additional 5 
min; d) mice were randomly divided into two groups and, 
after habituation to the predator odor chamber, they re-
ceived 10 mg/kg MDMA or 0.9% NaCl. After 60 min, each 
mouse was placed on the left side of the exposure cage 
and allowed to explore the compartments 
for 10 min; e) mice were randomly treated 
with 10 mg/kg MDMA or 0.9% NaCl. After 60 
min, the striatum was harvested to measure 
dopamine and its HVA and DOPAC; f) mice 
received 10 mg/kg MDMA or 0.9% NaCl and 
30, 60, and 120 min later blood samples were 
collected to measure serum corticosterone 
levels. Seven to 10 mice/group were used in 
each experiment.
A 60-min interval between injection and 
test exposure was chosen on the basis of 
published data (3,16). We have shown that 
plasma MDMA concentration already reaches 
a peak after 60 min (16) and therefore it 
seems reasonable to suggest that this is the 
most appropriate interval to analyze MDMA 
behavioral outcomes.
Statistical analysis
GraphPad Prism 5.0 software (GraphPad 
Softwares Inc., USA) was employed through-
out for statistical analysis. Parametric data 
were analyzed by the unpaired Student t-test 
or one-way ANOVA followed by Dunnett’s 
multiple comparison test. The Mann-Whitney 
U-test or Kruskal-Wallis test (KW) followed by 
Dunn’s multiple comparison tests was used 
to analyze non-parametric data. Moreover, 
analysis of covariance (ANCOVA) was per-
formed to determine the independence of 
changes observed in the elevated plus maze. 
In all experiments, P < 0.05 was considered 
to be significant. Data are reported as means 
± SEM.
Results
MDMA increases locomotor activity in 
the open field
Our first goal was to construct a dose-
response curve for the effects of MDMA in the 
open field. We observed that treatment with 
5.0, 8.0, 10, and 20 mg/kg MDMA increased 
the distance traveled in the total arena (F (6,48) = 72.61; 
P < 0.0001) and peripheral zone (8.0, 10, and 20 mg/kg; 
KW (42.10); P < 0.0001; Figure 1A). We also observed that 
MDMA at 1.0, 5.0, and 20 mg/kg increased the distance 
traveled in the central zone (KW (27.66); P = 0.0001) of the 
open field (Figure 1A). Similarly, we observed that MDMA at 
5.0, 8.0, 10, and 20 mg/kg increased the time spent in the 
total arena (KW (41.87); P < 0.0001) and in the peripheral 
zone (KW (42.00); P < 0.0001; Figure 1B); we also observed 
that MDMA at 1.0, 5.0, 10, and 20 mg/kg increased the time 
spent in the central zone (F (6,48) = 3.564; P < 0.01) of the 
Figure 2. Behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) on BALB/c male mice in the hole-board test. 
A, Distance traveled (cm); B, mean velocity (cm/s); C, number of head dips; D, time spent during head-dipping. Data are reported 
as means ± SEM for 10 animals/group. *P < 0.05 compared to control group (one-way ANOVA followed by Dunnett’s multiple 
comparison test). 
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open field (Figure 1B). Moreover, we observed an increase in 
the mean velocity (KW (43.07); P < 0.0001) and a decrease 
in frequency of both rearing (KW (41.24); P < 0.0001) and 
grooming (F (6,48) = 15.91; P < 0.0001) after treatment with 
MDMA at 5.0, 8.0, 10, and 20 mg/kg (Table 1). 
MDMA increases locomotor activity and decreases 
exploratory behavior in the hole board
Since there were no statistically significant differences 
among MDMA doses (5.0, 8.0, 10, and 20 mg/kg) in the 
open-field test (see Figure 1A and B), we performed the 
hole-board test using only 5.0 and 10 mg/kg MDMA-treated 
mice. We observed that MDMA-treated mice (5.0 and 10 
mg/kg) presented an increase in both distance traveled (F 
(2,27) = 63.02; P < 0.0001) and mean velocity (F (2,27) 
= 32.90; P < 0.0001; Figure 2A and B). Additionally, we 
observed that MDMA-treated mice (5.0 and 10 mg/kg) pre-
sented a decreased number (F (2,27) = 70.28; P < 0.0001) 
and time (F (2,27) = 51.94; P < 0.0001) of head-dipping 
(Figure 2C and D).
Table 1. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 10 mg/kg) on BALB/c male mice in the open field 60 min after treatment.
Open-field parameters Control MDMA 
(0.2 mg/kg)
MDMA 
(1.0 mg/kg)
MDMA 
(5.0 mg/kg)
MDMA 
(8.0 mg/kg)
MDMA 
(10 mg/kg)
MDMA 
(20 mg/kg)
Mean velocity (cm/s) 6.198 ± 0.51 5.881 ± 0.35 7.270 ± 0.34 12.65 ± 0.89* 13.91 ± 0.46* 16.14 ± 0.74* 15.02 ± 0.94*
Rearing (N) 27.13 ± 3.86 24.29 ± 2.45 30.38 ± 3.05 6.500 ± 1.31* 5.625 ± 1.99* 2.500 ± 0.63* 4.500 ± 0.94*
Grooming (N) 10.88 ± 1.89 9.000 ± 1.79 7.375 ± 1.76 1.000 ± 0.60* 0.000 ± 0.00* 0.000 ± 0.00* 0.625 ± 0.32*
Data are reported as means ± SEM for 7-8 animals/group. *P < 0.05 compared to control (one-way ANOVA followed by Dunnett’s 
multiple comparison test or Kruskal-Wallis test followed by Dunn’s multiple comparison test). 
Figure 3. Behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) on BALB/c male mice in the elevated plus-
maze test. A, Percent of open-arm entries and B, percent of open-arm time during the 5 min of the test. Data are reported as 
means ± SEM for 9-10 animals/group. *P < 0.05 compared to control (Student t-test or Mann-Whitney U-test). 
Differential behavioral outcomes of MDMA 433
www.bjournal.com.br Braz J Med Biol Res 44(5) 2011
MDMA induces anxiolytic-like behavior in the 
elevated plus maze
Since we did not observe any difference between 
5.0 and 10 mg/kg MDMA in the hole-board test (see 
Figure 2), we decided to use MDMA only at 10 mg/kg. 
Similarly to the results reported above, in the open 
field, mice treated with 10 mg/kg MDMA presented 
an increase in the distance traveled in the total arena 
(t (17) = 8.931; P < 0.0001), as well as in the periph-
eral (t (17) = 5.612; P < 0.0001) and central (U (3.0); 
P < 0.001) zones. We also observed that MDMA treat-
ment increased the time spent in the total arena (U (0.0); 
P < 0.0001), and in the peripheral (t (17) = 8.049; P < 
0.0001) and central (t (17) = 4.521; P < 0.001) zones. 
Moreover, we observed an increase in the mean ve-
locity (t (17) = 8.928; P < 0.0001) and a decrease in 
the frequency of both rearing (U (1.0); P < 0.001) and 
grooming (U (5.5); P < 0.001).
In the elevated plus maze, we observed that MDMA-
treated mice presented both increased entries (%) (t 
(17) = 2.510; P < 0.05) and time spent (%) (U (2.0); P < 
0.001) in the open arms (Figure 3A and B, respectively). 
As expected, the contrary was observed in the closed-
arm entries and time (t (17) = 2.510, P < 0.05; U (2.0); 
P < 0.001; Table 2). Furthermore, MDMA increased both 
distance traveled (t (17) = 5.101; P < 0.0001) and time 
spent moving (t (17) = 3.743; P < 0.001) in the total plus-
maze arena (Table 2). We also observed a decrease in 
the frequency of rearing (t (17) = 4.098; P < 0.001), risk 
assessment (U (0.5); P = 0.001) and total arm entries 
(t (17) = 4.284; P < 0.001; Table 2).
ANCOVA showed that time of exploration (%) in 
the open arms was not influenced by the number of 
entries (%) in the closed arms, which means that the 
differences found were caused only by MDMA treatment 
(F (1,16) = 0.97; P = 0.34).
Table 2. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 
10 mg/kg) on BALB/c male mice in the elevated plus maze 60 min 
after treatment.
Elevated plus-maze 
parameters
Control MDMA 
(10 mg/kg)
Distance traveled (cm) 1282 ± 63.17 1806 ± 82.41*
Time (s) 44.37 ± 5.03 85.42 ± 10.14*
Rearing (N) 22.40 ± 1.26 11.67 ± 2.39*
Risk assessment (N) 34.63 ± 10.29 18.50 ± 2.56*
Arm entries (N) 38.60 ± 2.50 16.11 ± 4.80*
Closed arms entries (%) 69.70 ± 14.56 48.99 ± 21.14*
Closed arms time (%) 94.84 ± 9.02 17.50 ± 29.78*
Data are reported as means ± SEM for 9-10 animals/group. 
*P < 0.05 compared to control (Student t-test or Mann-Whitney 
U-test). 
Table 3. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 
10 mg/kg) on defensive behavior on BALB/c male mice in response 
to cat odor 60 min after treatment.
Defensive behavior 
parameters
Control MDMA 
(10 mg/kg)
Time in home chamber (s) 369.4 ± 48.0 519.6 ± 36.6*
Time in tunnel (s) 63.8 ± 12.5 25.4 ± 15.6*
Entries into exposure cage (N) 7.2 ± 2.3 2.6 ± 1.9*
Entries into contact zone (N) 3.7 ± 0.7 1.5 ± 0.8*
Grooming frequency (N) 4.1 ± 2.1 4.5 ± 2.0 
Risk assessment (N) 3.7 ± 0.9 2.0 ± 1.1*
Data are reported as means ± SEM for 10 animals/group. *P < 
0.05 compared to control (Student t-test). 
Figure 4. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on the striatal content and turnover of dopamine 
and its metabolites on BALB/c male mice. A, Dopamine; B, dihydroxyphenylacetic acid (DOPAC); C, homovanillic acid 
(HVA); D, dopamine turnover (DOPAC+HVA/DA). Data are reported as means ± SEM for 9-10 animals/group. *P < 0.05 
compared to control (Student t-test or Mann-Whitney U-test). 
Figure 5. Effects of 3,4-methylenedioxymethamphetamine 
(MDMA) on corticosterone serum levels 30, 60, and 120 min after 
administration to BALB/c male mice. Data are reported as means 
± SEM for 10 animals/group. *P < 0.05 compared to control (one-
way ANOVA followed by Dunnett’s multiple comparison test).
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MDMA increases defensive behavior in the presence 
of cat odor
Finally, we decided to perform a defensive behavior test 
in order to compare the data obtained with the behavioral 
results reported above. We observed that MDMA increased 
the time spent in the home chamber (t (18) = 7.843; P < 
0.001) and decreased the time spent in the tunnel (t (18) 
= 6.063; P < 0.001). MDMA also decreased the number of 
entries into the exposure cage (t (18) = 4.951; P < 0.001) 
and into the contact zone (t (18) = 4.610; P < 0.001), and the 
frequency of risk assessments was reduced as well (t (18) 
= 3.791; P < 0.001; Table 3). Grooming was not changed 
by MDMA treatment.
MDMA increases dopamine turnover in the striatum
Based on the results of the reported behavioral tests, 
we thought it would be interesting to analyze the effects 
of a similar protocol of MDMA treatment on dopamine 
level and turnover in the striatum. We showed that MDMA 
increased striatal dopamine (U (17); P < 0.05), DOPAC (t 
(17) = 2.253; P < 0.05) and HVA (t (17) = 4.906; P < 0.0001) 
contents (Figure 4A,B and C, respectively). Furthermore, 
we observed that dopamine turnover (DOPAC+HVA/DA) 
was higher in MDMA-treated mice than in control mice 
(t (17) = 2.543; P < 0.05; Figure 4D).
MDMA increases serum corticosterone levels
Finally, we analyzed the level of corticosterone in serum 
after 30, 60, and 120 min of MDMA (10 mg/kg) treatment. 
We showed that MDMA increased serum corticosterone 
might have been confounded by alterations in locomotor 
activity. A similar interpretation seems to be valid for the 
behavioral data reported here in the open field, hole board 
and plus maze, indicating that MDMA altered locomotor 
activity rather than affecting the levels of anxiety. Indeed, 
MDMA increased all locomotion parameters measured in 
the three apparatuses, in agreement with data reported 
by Fletcher et al. (27). Therefore, we believe that the data 
obtained here for MDMA treatment in the predator odor be-
havioral test and neurochemical/hormonal analysis might 
shed some light on the discussion regarding anxiogenic 
versus anxiolytic-like responses. 
Defensive behaviors are innate and unconditioned 
reactions of an organism toward actual or potential threats 
(18). Anxiety, fear and stress are behavioral outcomes of 
the activation of CNS defensive systems (28). Rodents 
become defensive in the presence of a predator (28), of 
predator odor (18) and also when placed in strange places 
(29). The data obtained here using the predator odor test 
apparatus showed that MDMA treatment increased time 
spent in the home chamber. Moreover, MDMA decreased 
the number of risk assessments in the tunnel and in the 
exposure chamber. These data strongly suggest that 
MDMA increased the animals’ level of anxiety. Indeed, 
similar behavioral results were reported in studies using 
a similar apparatus after different stressors (30) or fear-
eliciting stimuli (18,29). This hypothesis is consistent with 
results reported using the social interaction test (10,31). 
Stressors are known to increase serum corticosterone 
levels (3,14) and catecholaminergic activity in the CNS 
(32,33). An increase in serum corticosterone level as well 
as in striatal dopamine level and turnover was shown in 
the present study after MDMA treatment. Hence, it seems 
reasonable to suggest that MDMA has an anxiogenic-like 
effect on mice. Indeed, we have already reported that 
MDMA (10 mg/kg) increased hypothalamic noradrenergic 
activity (3). Limbic brain areas, such as hypothalamus, 
amygdala and hippocampus, exhibit rapid and large in-
creases in noradrenaline turnover in anxiogenic situations 
(32,34). The mesolimbic dopaminergic system has already 
been related to anxiety-like responses (35). Correlation 
studies between tyrosine hydroxylase activity, dopamine 
level and anxiety-like responses have suggested that de-
creasing tyrosine hydroxylase activity, which in turn leads 
to decreased dopamine levels, is negatively related to 
the levels of anxiety measured in a plus-maze apparatus 
(36,37). Furthermore, increases in serum corticosterone 
levels were reported after application of physical, psycho-
logical and chemical stressors (3,14,38,39). 
Taken together, the present data suggest an anxio-
genic-like effect of acute MDMA treatment despite the fact 
that the expression of behavioral anxiety was impaired 
in some of the behavioral tests used, most probably as a 
consequence of the locomotor action of MDMA. Research 
on behavioral, endocrine and neurochemical effects of 
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levels (KW (38.90); P < 0.0001) approximately 6-fold at all 
times analyzed (Figure 5).
Discussion
We reported here the differential behavioral outcomes 
for MDMA administration in mice. We showed that the 
magnitude and extent of the behavioral outcome observed 
depended on the behavioral test used. Thus, MDMA in-
duced a dose-dependent increase in the distance traveled 
and in the time spent moving in the open field. Furthermore, 
MDMA decreased the exploratory activity in the hole board, 
as measured by number of head dippings and time spent in 
head dipping. MDMA also increased the number of open- 
arm entries and time spent in open-arm exploration in a 
plus-maze apparatus. Finally, using a predator odor test 
device, we showed that MDMA increased time spent away 
from the aversive stimulus and decreased the number of 
risk assessments in the tunnel of the apparatus.
Anxiety level is operationally inferred as suggested 
elsewhere (20), i.e., as a response to a situation in which 
behavior is influenced by two opposing motivational forces 
(e.g., a natural curiosity to explore unexplored or novel 
areas versus an aversion to open areas). Thus, increments 
in number of entries or in the time spent by rodents in the 
plus-maze open arms commonly indicate the presence 
of decreased levels of anxiety (20,21). Anxiogenic drugs 
are reported to increase the time spent in the peripheral 
zone of the open field, decreasing, at the same time, the 
permanence of the animal in the central zones (22,23). 
Conversely, anxiolytic drugs have been shown to reduce 
exploration of the peripheral open-field zones (24). Here, 
we showed that MDMA-treated mice traveled an increased 
distance (cm) in the peripheral and central open-field zones 
as well as in the hole-board apparatus; we also showed 
an increase in time spent and number of entries into plus-
maze open arms. Thus, at first glance these data suggest 
an anxiolytic-like profile for MDMA in mice, in agreement 
with data reported elsewhere (8).
MDMA, like other amphetamines, is known to increase 
nigrostriatal DA activity (25) and consequently increases 
the distance traveled, as reported here. The existence 
of a positive correlation between distance traveled and 
nigrostriatal dopaminergic activity is of common knowl-
edge. Dawson et al. (26) showed that rats treated with 
d-amphetamine presented an increase in number of en-
tries into the open arms of the plus maze. However, the 
drug concomitantly increased the total distance traveled 
and the mean velocity of the animals in the closed arms 
of the plus maze. These data led these investigators to 
suggest that psychomotor-stimulating compounds such as 
amphetamines might have an anxiolytic-like profile in the 
elevated plus maze. According to Lister (21), alteration of 
animal behavior in the plus maze, which somehow was 
interpreted to correspond to decreased levels of anxiety, 
drugs on anxiety, stress and fear in laboratory animals 
are implicitly motivated by an expectation that such re-
sults may be useful and extrapolated to humans. Thus, 
the present data suggest that MDMA use might increase 
the levels of anxiety, stress and fear in humans. Further-
more, it should not be forgotten that these feelings are 
common components of aggressive responses in labora-
tory animals, wild-type animals and humans (40). 
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